Houston Pharmacy Shut Down by DEA for Ignoring Drug Abuse Warnings
Published Date: 10/17/2025
Notice
Summary
Hovic Pharmacy in Houston lost its DEA license because it filled many controlled substance prescriptions in ways that didn’t follow pharmacy rules, risking drug abuse and illegal distribution. This decision means Hovic can no longer legally handle these drugs, protecting public safety. The change is effective immediately, impacting the pharmacy’s business and its customers.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Hovic Pharmacy
Hovic Pharmacy in Houston, Texas (DEA registration No. FH5569112) had its DEA registration revoked, effective immediately. This means the pharmacy can no longer legally handle or dispense controlled substances, closing that part of its business.
Customers Lose Access at That Location
If you were a customer of Hovic Pharmacy in Houston, Texas, you can no longer have controlled-substance prescriptions filled there effective immediately (published October 17, 2025). You will need to get those prescriptions filled at a different pharmacy or by another provider.
Action Aimed to Protect Public Safety
The DEA found the pharmacy unlawfully released about 13,135 controlled substance tablets and about a 3,478 days' supply of promethazine with codeine into the community during December 17, 2018 through March 15, 2021; revoking the registration is intended to prevent further unlawful distribution. The decision takes effect immediately and is intended to protect the local community from diversion and abuse.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-19577 — Shannon Wagner, D.O.; Decision and Order
Shannon Wagner, D.O., from Green Bay, Wisconsin, applied for a DEA registration but was initially denied because she was excluded from federal health programs like Medicare and Medicaid. After a hearing, the judge recommended approving her application, and the DEA agreed, allowing her to move forward. This decision affects Dr. Wagner’s ability to legally handle controlled substances and participate in federal programs, clearing the way for her professional activities without financial penalties.
Next: 2025-19579 — David S. Pecora, P.A.; Decision and Order
David S. Pecora, P.A. from Minnesota tried to get a DEA registration but didn’t respond to the government’s concerns about false info on his applications. Because he didn’t ask for a hearing or explain himself, the DEA denied his registration, saying it’s not in the public’s best interest. This means no DEA registration for Pecora, and it’s official as of late 2024.